Calidi Biotherapeutics, Inc. financial data

Symbol
CLDI, CLDI-WT on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
4475 Executive Drive, Suite 200, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
First Light Acquisition Group, Inc. (to 9/19/2023)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 39.8 % +910%
Debt-to-equity -219 % -525%
Return On Equity 261 % +333%
Return On Assets -219 % -125%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.08M shares
Common Stock, Shares, Outstanding 6.47M shares
Entity Public Float 43.3M USD -81.1%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 5.33M shares +507%
Weighted Average Number of Shares Outstanding, Diluted 5.33M shares +507%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 12.1M USD -31.8%
Operating Income (Loss) -29.6M USD +13.5%
Nonoperating Income (Expense) 6.34M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -23.2M USD +53.5%
Income Tax Expense (Benefit) 20K USD +5.26%
Net Income (Loss) Attributable to Parent -23.2M USD +27.5%
Earnings Per Share, Basic 15.1 USD/shares +90.2%
Earnings Per Share, Diluted 15.1 USD/shares +90.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 800K USD
Accounts Receivable, after Allowance for Credit Loss, Current 870 USD
Assets, Current 1.63M USD +104%
Property, Plant and Equipment, Net 1.06M USD
Operating Lease, Right-of-Use Asset 3.52M USD -23.1%
Other Assets, Noncurrent 227K USD
Assets 6.43M USD -85.4%
Accounts Payable, Current 487K USD +1652%
Accrued Liabilities, Current 5.79M USD +1574%
Liabilities, Current 13.1M USD +59.5%
Operating Lease, Liability, Noncurrent 2.46M USD -30.6%
Other Liabilities, Noncurrent 1.5M USD
Liabilities 18.2M USD +42.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -27K USD
Retained Earnings (Accumulated Deficit) -113M USD -826%
Stockholders' Equity Attributable to Parent -11.8M USD +81.6%
Liabilities and Equity 6.43M USD -85.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.83M USD -23.3%
Net Cash Provided by (Used in) Financing Activities 3.01M USD -20.5%
Net Cash Provided by (Used in) Investing Activities -5K USD +96.4%
Common Stock, Shares Authorized 330M shares
Common Stock, Shares, Issued 6.47M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -806K USD -247%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.05M USD -53.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 24K USD +100%
Deferred Tax Assets, Valuation Allowance 23.9M USD +53.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Cash and Cash Equivalents, Period Increase (Decrease) -465K USD
Deferred Tax Assets, Gross 25M USD +60.7%
Operating Lease, Liability 3.58M USD -20.5%
Depreciation 401K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -23.3M USD +53.6%
Lessee, Operating Lease, Liability, to be Paid 4.17M USD
Property, Plant and Equipment, Gross 2.25M USD
Operating Lease, Liability, Current 1.12M USD +16.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.51M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.46M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 596K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 485K USD
Deferred Tax Assets, Operating Loss Carryforwards 15.2M USD +50.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 1.52M USD +22.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3K USD
Operating Lease, Payments 349K USD +2.95%
Additional Paid in Capital 101K USD -44.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3.93M USD -30.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%